Heron Ther­a­peu­tics launch­es patent suit against My­lan over po­ten­tial gener­ic for chemo-re­lat­ed nau­sea

Heron Ther­a­peu­tics filed suit in Delaware fed­er­al court on Fri­day to block My­lan Phar­ma­ceu­ti­cals’ gener­ic ver­sion of a drug used for chemother­a­py-as­so­ci­at­ed nau­sea.

Heron’s Cin­van­ti was first ap­proved in 2017 as an IV for­mu­la­tion to pre­vent nau­sea and vom­it­ing in pa­tients tak­ing chemo, ri­val­ing Mer­ck’s Emend. Though Cin­van­ti con­tains the same ac­tive in­gre­di­ent, aprepi­tant, Heron mar­ket­ed the drug as a new op­tion for pa­tients with­out an ad­di­tive called polysor­bate 80, which had been linked to ana­phy­lax­is and in­jec­tion site re­ac­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.